MINISTERIODE ECONOMÍAY COMPETITIVIDAD

Centro para elDesarrolloTecnológico Industrial

Magali Poinot, Legal Manager within the Innovative Medicines Initiative (IMI) Executive Office

Magali Poinot is the Legal Manager at the Innovative Medicines Initiative, mainly responsible for coordinating and monitoring the management of grant negotiations and award; monitoring and advising on the implementation of the IMI Intellectual Property policy by promoting open innovation in public-private research collaborations, coordinating activities of the IMI States Represen-tatives Group (SRG). Magali is a qualified lawyer, specialising in European Community-funded Research & Development and innovation programmes and Intellectual Property issues in Framework Programme projects.

Nima Behkami, Director Strategic Alliance Merck MSD

Nima Behkami, PhD, is a Director of Strategic Alliances in the Office of Chief Information Officer at Merck Sharp & Dohme (MSD). Through prescription medicines, vaccines, biologic therapies, and animal health products, MSD operates in more than 140 coun-tries to deliver innovative health solutions. Dr. Behkami’s responsibilities include creating partnerships from technology transfer to mergers and acquisitions. He is a member of the advisory board at Founders Workbench, and advises the UKTI GREAT Tech Awards. Dr. Behkami held a NIH Fellowship in medicine at Brigham & Women’s Hospital in Boston, and received his degree from Harvard Medical School.

Rémi Droller, Managing Partner. Kurma Partners

MS in molecular biology (Paris VI University) and MS in finance and Innovation management (Masternova – AgroPariTech). He was previously with CDC Innovation from 2000 to 2003 and with AGF Private Equity (now Idinvest Partners) from 2003 to 2010 where he was in charge of the development of the Life Sciences investment activity. During this period, Rémi serves on the board of several investee companies such as Adocia, Bioalliance Pharma (listed on Euronext), Domain Therapeutics, Integragen (listed on Alternext), Novagali Pharma (listed on Euronext), Prosensa and Zeland Pharma. Rémi joined Kurma in September 2010.

Infoday IMI2, 3rd and 4th calls for proposals

www.imi.europa.eu www.vhir.org

For more info: Research Projects Promotion Unit (ugp@vhir.org)

Barcelona 26th of November 2014Fundació Hospital Universitari Vall d’Hebron

Institut de Recerca (VHIR) Sala de Actes • Pavelló Docent

MINISTERIODE ECONOMÍAY COMPETITIVIDAD

Centro para elDesarrolloTecnológico Industrial

C

M

Y

CM

MY

CY

CMY

K

09:15 - 10:00 h Registration

10:00 - 10:15 h Introduction Dr. Joan X. Comella, Director, Vall d’Hebron Institute of Research

10:15 - 11:00 h Presentation from the industry, EFPIA(Presentation of the dynamics behind EFPIA and the calls for proposals - Brief overview of the topics to come in the second call, and fields of interests for the future)

Dr. Thomas Eichholtz, Chief Scientific Officer and Corporate Director of R&D, Almirall, EFPIA representative

11:00 - 11:30 h Testimonies from participants in IMI (The good and the bad: giving example of what it’s like to participate in IMI)

Dr. Jordi Serra, CEO Neuroscience Technologies

Dr. Eva Molero, CEO at Synapse Research Management Partners

11:30 - 12:00 h Spanish participation in IMI2(Overview of the Spanish participation, and further challenges in IMI2)

Dr. Marta Gomez Quintanilla, Spanish representative H2020 Health Challenge and IMI2, CDTI

12:00 - 12:30 h Co�ee Break

12:30 - 13:30 h IMI2 Framework (IMI representatives)(Rules for participation in IMI2, how do the schemes work, does and don’t, tips for participation)

Dr. Hugh Laverty, Senior Scientific Project Manager, IMI Executive OfficeDr. Magali Poinot, Legal Manager, IMI Executive Office

13:30 - 14:30 h Lunch break*

14:30 - 16:00 h 3rd and 4th call for proposals: The topics (Presentation of the topics + Questions and answers)

Dr. Nima Behkami, Director Strategic Alliance Merck MSDDr. Hugh Laverty, Senior Scientific Project Manager, IMI Executive OfficeDr. Marta Gomez Quintanilla, Spanish representative H2020 Health Challenge and IMI2, CDTI

16:00-16:45 h Session with Venture capitalists and example of academic spino�s(Presentation of the business interests in venture capital, the future of IMI projects for SMEs and spin offs)

Dr. Nima Behkami, Director Strategic Alliance Merck MSDDr. Rémi Droller, Managing Partner, Kurma Partners

16:45 - 17:00 h Wrap up and conclusions

Thomas Eichholtz, Chief Scientific Officer and Corporate Director of R&D, at Almirall. EFPIA representative

Thomas has a PhD in Biology from the Netherlands Cancer Institute in Amsterdam and is a translational scientist expert. Since September 2014, he is Chief Scientific Officer and Corporate Director of R&D of Almirall. He joined Almirall in 2012 as a Senior Director and Head of Discovery. Prior to that he was VP Project Management for the Respiratory & Inflammation iMed at AstraZe-neca in Mölndal (Sweden), after leading the R&I Research Area and the R&I Translational Sciences group in Charnwood and Lund. He also worked for Pfizer as Head of Biology in Paris, after starting his career at Wellcome/GlaxoWellcome/GSK.

Jordi Serra, CSO, Neuroscience Technologies Ltd., Barcelona, London

Dr Jordi Serra completed his residency in Neurology at the University of Barcelona and a fellowship at the Oregon Health Sciences University in Portland, USA. Dr Serra has produced pioneering work on the recording of abnormal activity in nociceptors using microneurography, both in animals and in patients, as a fully translational approach to develop new pain drugs and to detect neurotoxicity. In 2005, he founded Neuroscience Technologies in Barcelona, and in 2010 expanded to London, where it offers preclinical and clinical human studies. Neuroscience Technologies is the only SME of Europain, a project funded by the EU Innova-tive Medicines Initiative.

Eva Molero, CEO at Synapse Research Management Partners

Eva Molero. Co-founder and CEO of Synapse Partners Research Management, a company managing complex research projects in the biomedical field. With a background in legal affairs and marketing, she has worked for over 10 years in the management of European projects and technology transfer for the Universitat Pompeu Fabra and the IMIM Foundation. Synapse participates in six IMI projects, mainly taking the lead in respect to the project management, communication, business planning and sustainability. These IMI projects mobilize resources of about 160 million euros.

Marta Gomez Quintanilla, Spanish representative H2020 Challenge Health and IMI2

Working for CDTI (Centre for the Development of Industrial Technology), public company depending from the Ministry of Economy and Competitiveness, since 2003, she is fully devoted to Horizon 2020 work in the EU Programmes Division, within the Directorate of International Programmes. Firstly acting as National Contact Point in different themes (NMP, KBBE and Health), giving support to participants, organizing courses and events, reporting, etc. and then as expert in KBBE and in 2008 as expert in Health and Innovative Medicines Initiative (IMI), she is now the Spanish IMI Representative & Health Delegate since 2010.

Hugh Laverty, Senior Scientific Project Manager within the Innovative Medicines Initiative (IMI) Executive Office.

Within the Executive Office, Hugh’s main responsibilities include managing specific projects mainly focused on drug delivery, CMC and lead discovery. He plays an active role in determining measurement criteria to assess the success of public-private partnerships and oversees the Executive Office’s engagement with Small and Medium Enterprises (SMEs). Prior to joining IMI he worked as Industry Programme Manager at the Centre for Drug Safety Science at the University of Liverpool, UK. He has extensive experience in the Biotech sector having spent 10 years working at Renovo plc in Manchester, UK. While at Renovo he was a Disco-very Manager identifying and developing recombinant proteins as novel therapeutics for the prevention of dermal scarring.

* Lunch is not provided by the organisation

SpeakersAgenda

C

M

Y

CM

MY

CY

CMY

K